相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Kei Namba et al.
MOLECULAR CANCER RESEARCH (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Tadashi Akiba et al.
CLINICAL CANCER RESEARCH (2018)
Vitamin D Receptor Signaling and Cancer
Moray J. Campbell et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2017)
Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase InhibitorsandTriggers Epithelial-to-Mesenchymal Transition
Wen Hwang et al.
CANCER RESEARCH (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Shigenari Nukaga et al.
CANCER RESEARCH (2017)
Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo
Alissa R. Verone-Boyle et al.
ONCOTARGET (2016)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
Zheng-Hai Tang et al.
ONCOTARGET (2016)
Lung cancer epidemiology: contemporary and future challenges worldwide
Joanna Didkowska et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor
Paul A. Dickinson et al.
DRUG METABOLISM AND DISPOSITION (2016)
The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer
Pankaj G. Vashi et al.
BMC CANCER (2015)
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Yoshihisa Kobayashi et al.
CLINICAL CANCER RESEARCH (2015)
Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D
Youngtae Jeong et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Serum vitamin D, vitamin D binding protein, and lung cancer survival
Gabriella M. Anic et al.
LUNG CANCER (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations
Qiuhong Zhang et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?
Joshua Bauml et al.
LUNG CANCER (2013)
Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
Jong-Mu Sun et al.
PLOS ONE (2013)
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
Santosh Upadhyay et al.
Cancers (2013)
Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study
Steinar Tretli et al.
CANCER CAUSES & CONTROL (2012)
Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction
Ting-Yuan David Cheng et al.
CANCER CAUSES & CONTROL (2012)
Dietary Vitamin D3 and 1,25-Dihydroxyvitamin D3 (Calcitriol) Exhibit Equivalent Anticancer Activity in Mouse Xenograft Models of Breast and Prostate Cancer
Srilatha Swami et al.
ENDOCRINOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline
Michael F. Holick et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs
Jin-Haeng Chung et al.
LUNG CANCER (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases
Camilla M. T. Sagerup et al.
THORAX (2011)
Survival Differences by Gender for Resected Non-small Cell Lung Cancer A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study
Hiroyuki Sakurai et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Daniele Merico et al.
PLOS ONE (2010)
Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier
Juan Kong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
Circulating 25-Hydroxyvitamin D, VDR Polymorphisms, and Survival in Advanced Non-Small-Cell Lung Cancer
Rebecca Suk Heist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
Miguel A. Molina-Vila et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
Heather A. Wakelee et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
H Shigematsu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals
XH Xie et al.
NATURE (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
H Shigematsu et al.
CANCER RESEARCH (2005)
Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer
J Welsh et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2002)
Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling
HG Pálmer et al.
JOURNAL OF CELL BIOLOGY (2001)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
